Basic Information
Ovidrel Solution for Injection 250 mcg
INJECTION, SOLUTION
Regulatory Information
SIN13015P
July 13, 2004
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 3, 2025
XG03GA08
Company Information
Active Ingredients
Strength: 250 mcg
Detailed Information
Contraindications
**Contraindications** - Hypersensitivity to the active substance or to any of the excipients - Tumours of the hypothalamus and pituitary gland - Ovarian enlargement or cyst unrelated to polycystic ovarian syndrome - Gynaecological haemorrhages of unknown aetiology - Ovarian, uterine or mammary carcinoma - Active thromboembolic disorders Ovidrel® must not be used in conditions when an effective response cannot be obtained, such as - primary ovarian failure - malformations of sexual organs incompatible with pregnancy - fibroid tumours of the uterus incompatible with pregnancy - postmenopausal women
Indication Information
**Therapeutic indications** Ovidrel® is indicated in the treatment of - Women undergoing superovulation prior to assisted reproductive technologies (ART) such as in vitro fertilisation (IVF): Ovidrel® is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth, - Anovulatory or oligo-ovulatory women: Ovidrel® is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.